Selpercatinib (LOXO-RET 18036)

Selpercatinib, a RET-inhibitor for children with solid tumours and brain tumours

Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Recruitment completed

Summary

In this clinical trial children, adolescents and young adults between 12 and 21 years will be treated with Selpercatinib (Loxo-292).

Selpercatinib specifically inhibits the Receptor-Tyrosine Kinase (RET), meaning it blocks a type of enzyme (kinase) and helps to prevent the cancer cells from growing. Before the treatment starts, the identification of a RET gene alteration must be determined using laboratory testing. Therefore, only advanced tumours with RET-alterations  after standard therapy are eligible. 

Selpercatinib is taken orally over a 28-day cycle as gelatine capsules or as a liquid suspension.

Recruitment was closed on May 1st, 2024.

Main inclusion criteria

  • Age: 12 to 21 years
  • advanced solid tumors or primary tumors of the central nervous system
  • Confirmed alteration of the RET-gene (mutations and fusions)
  • Karnofsky or Lansky > 50

Sponsor

Loxo Oncology Inc., wholly owned subsidiary of Eli Lilly and Company

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzinformationen